Yazar "Can, G." seçeneğine göre listele
Listeleniyor 1 - 6 / 6
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Assessment of thrombin formation in patients with ulcerative colitis without a history of thrombotic events(Wiley-Blackwell, 2013) Demir, M.; Halhalli, S.; Tezel, A.; Ustundag, A.; Can, G.; Umit, E.[Abstract Not Available]Öğe EFFECTS OF SACCHAROMYCES BOULARDII ON ANTIBIOTIC INDUCED OROCECAL TRANSIT IN RATS(Akademiai Kiado Rt, 2014) Duman, D. G.; Akin, H.; Deniz, M.; Can, G.; Yegen, B. C.Clarithromycin is an antibiotic widely used for Helicobacter pylori (H. pylori) eradication and together with amoxicillin and proton pump inhibitors they constitute the first line triple treatment regimen against H. pylori. Diarrhoea is one of the major drawbacks during H. pylori eradication and is majorly attributed to clarithromycin, while Saccharomyces boulardii is a probiotic and is shown to be effective in the treatment of antibiotic associated diarrhoea. We aimed to evaluate the effect of clarithromycin on orocecal transit in rats and to identify whether the supplementation with S. boulardii has a role on orocecal transit index. Adult rats of both sexes were divided into two groups to determine immediate or chronic effects of S. boulardii and clarithromycin on orocecal transit. The first group was given single dose of the test drug, while the second group received the test drugs for one week through orogastric intubation. Both groups were randomly distributed into four subgroups; the placebo group (group A), the S. boulardii group (group B), the clarithromycin group (group C), and the co-administration that is clarithromycin plus S. boulardii group (group D). Rats were given 20 mg kg(-1) clarithromycin and 500 mg kg(-1) S. boulardii. We did not find any difference among the subgroups in group 1, where only single dose of the test drugs was administered. In chronic administration group, that is group 2, significant differences among the subgroups were observed (P=0.004). Post-hoc comparisons of orocecal transit index between group 2A and 2C and 2C and 2D were significantly different (P=0.013 and P=0.005, respectively). Our results show that long term clarithromycin administration leads to rapid orocecal transit index and S. boulardii supplementation to clarithromycin can abolish this adverse effect in rats. Those findings suggest the beneficial use of S. boulardii in H. pylori eradication regimens.Öğe The efficacy of tyrosine kinase inhibitor dasatinib on colonic mucosal damage in murine model of colitis [Meeting Abstract](Oxford Univ Press, 2016) Can, G.; Ayvaz, S.; Can, H.; Karaboga, I.; Demirtas, S.; Aksit, H.; Yilmaz, B.[Abstract Not Available]Öğe The rate of drug usage and side-effects in inflammatory bowel disease(Oxford Univ Press, 2014) Can, G.; Tezel, A.; Unsal, G.; Ustundag, A.; Umit, H.; Soylu, A. R.[Abstract Not Available]Öğe Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model(Clinical & Exper Rheumatology, 2015) Pamuk, O. N.; Can, G.; Ayvaz, S.; Karaca, T.; Pamuk, G. E.; Demirtas, S.; Tsokos, G. C.Objective. The pathogenesis of fibrosis in scleroderma (SSc) is unknown. TGF-beta and platelet-derived growth factor are important in the development of fibrosis and tyrosine kinases are involved in these pathways. The possible antifibrotic effects of various kinase inhibitors in SSc have been studied before. Spleen tyrosine kinase (Syk) is a protein tyrosine kinase which activates intracellular signal transduction pathways; and has been claimed to be involved in the pathogenesis of systemic autoimmune diseases. Inhibition of Syk suppresses IgE-and IgG-associated FcR signal activation in various cell types; and suppresses experimental arthritis and skin and kidney disease in lupus-prone mice. We investigated the ability of a small drug, the Syk inhibitor, fostamatinib, to protect mice from bleomycin-induced SSc. Methods. Four study groups of BALB/c mice were included into this study: control, bleomycin (administered subcutaneously to BALB/c mice for 21 days), bleomycin and fostamatinib (mice fed with chow containing a Syk inhibitor for 21 days), and fostamatinib alone groups. Skin and lung tissue specimens were obtained and evaluated histologically. Results. Treatment with fostamatinib significantly reduced skin thickness and fibrosis. Mice treated with fostamatinib also displayed less fibrosis and inflammation in the lung tissue. Following fostamatinib treatment, Syk, phospho-Syk, and TGF-beta expression decreased in both skin and lung tissues. Conclusion. The Syk inhibitor fostamatinib prevented bleomycin-induced fibrosis and inflammation in the skin and in the lung. The anti-fibrotic effect of fostamatinib is linked to reduced Syk phosphorylation and TGF-beta expression. The Syk pathway appears as a potential molecular target for therapeutic intervention in SSc.Öğe Time-to-diagnosis in inflammatory bowel disease(Oxford Univ Press, 2014) Can, G.; Tezel, A.; Unsal, G.; Ustundag, A.; Umit, H.; Soylu, A. R.[Abstract Not Available]
